全文获取类型
收费全文 | 3357篇 |
免费 | 193篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 98篇 |
妇产科学 | 124篇 |
基础医学 | 440篇 |
口腔科学 | 95篇 |
临床医学 | 268篇 |
内科学 | 632篇 |
皮肤病学 | 82篇 |
神经病学 | 270篇 |
特种医学 | 65篇 |
外科学 | 368篇 |
综合类 | 19篇 |
一般理论 | 3篇 |
预防医学 | 517篇 |
眼科学 | 93篇 |
药学 | 224篇 |
中国医学 | 23篇 |
肿瘤学 | 217篇 |
出版年
2023年 | 40篇 |
2022年 | 34篇 |
2021年 | 138篇 |
2020年 | 101篇 |
2019年 | 157篇 |
2018年 | 171篇 |
2017年 | 118篇 |
2016年 | 110篇 |
2015年 | 116篇 |
2014年 | 177篇 |
2013年 | 208篇 |
2012年 | 298篇 |
2011年 | 312篇 |
2010年 | 176篇 |
2009年 | 150篇 |
2008年 | 226篇 |
2007年 | 189篇 |
2006年 | 162篇 |
2005年 | 160篇 |
2004年 | 138篇 |
2003年 | 87篇 |
2002年 | 91篇 |
2001年 | 14篇 |
2000年 | 10篇 |
1999年 | 8篇 |
1998年 | 11篇 |
1997年 | 13篇 |
1996年 | 11篇 |
1995年 | 10篇 |
1994年 | 7篇 |
1993年 | 6篇 |
1992年 | 7篇 |
1991年 | 9篇 |
1990年 | 6篇 |
1989年 | 16篇 |
1988年 | 12篇 |
1987年 | 8篇 |
1986年 | 4篇 |
1985年 | 3篇 |
1984年 | 8篇 |
1983年 | 6篇 |
1982年 | 3篇 |
1981年 | 3篇 |
1979年 | 4篇 |
1977年 | 3篇 |
1976年 | 3篇 |
1974年 | 4篇 |
1968年 | 2篇 |
1965年 | 2篇 |
1934年 | 2篇 |
排序方式: 共有3569条查询结果,搜索用时 15 毫秒
1.
Eloise R. Galligan Leila H. Shayegan Christine T. Lauren Kimberly D. Morel 《Pediatric dermatology》2019,36(5):753-754
Shaving and other modes of epilation can cause undue anxiety, pain, or skin irritation in children. Here, we present hair trimming as a safe, painless, and cost‐effective alternative for patients with unwanted hair which may be performed indefinitely or until the child is old enough to direct management. In select cases, removing unwanted hair using this technique may facilitate dermatologic surveillance. 相似文献
2.
3.
Hassan Vahidnezhad Leila Youssefian Amir Hossein Saeidian Sirous Zeinali Andrew Touati Maryam Abiri Soheila Sotoudeh Sara Norouz‐zadeh Niloufar Amirinezhad Nikoo Mozafari Maryam Daneshpazhooh Hamidreza Mahmoudi Mohammad Hamid Jonathan P. Bradfield Cecilia E. Kim Hakon Hakonarson Jouni Uitto 《Experimental dermatology》2019,28(10):1118-1121
Autozygosity mapping (AM) is a technique utilised for mapping homozygous autosomal recessive (AR) traits and facilitation of genetic diagnosis. We investigated the utility of AM for the molecular diagnosis of heterogeneous AR disorders, using epidermolysis bullosa (EB) as a paradigm. We applied this technique to a cohort of 46 distinct EB families using both short tandem repeat (STR) and genome‐wide single nucleotide polymorphism (SNP) array‐based AM to guide targeted Sanger sequencing of EB candidate genes. Initially, 39 of the 46 cases were diagnosed with homozygous mutations using this method. Independently, 26 cases, including the seven initially unresolved cases, were analysed with an EB‐targeted next‐generation sequencing (NGS) panel. NGS identified mutations in five additional cases, initially undiagnosed due to the presence of compound heterozygosity, deep intronic mutations or runs of homozygosity below the set threshold of 2 Mb, for a total yield of 44 of 46 cases (95.7%) diagnosed genetically. 相似文献
4.
ABSTRACTIntroduction: Skin conditions are common and highly varied in their etiology; therefore, a diverse array of therapeutics are utilized. Drug safety studies in dermatology can be challenging as there are over 3000 diagnoses to consider. As a result, dermatologists rely on data from multiple sources including clinical trials and real-world evidence.Areas covered: In this review, we cover the main sources of safety data available, their strengths and weaknesses and how dermatologists should utilize such data. We use real-world examples of the different types of adverse events reported and how they are best captured by either randomized controlled trials or post-marketing pharmacovigilance methods. With multiple new therapies in dermatology, such as dupilumab for atopic dermatitis and janus-kinase inhibitors for alopecia areata the specialty is awash with evolving high-level evidence for their use. It is important to understand the optimal way to assess safety from trials but also appreciate the need for ongoing capture of safety data in clinical practice.Expert opinion: In dermatology, there is a plethora of conditions to treat and clinical trials, post-marketing surveillance, such as drug registries and spontaneous reporting, all enable dermatologists to gain a more comprehensive understanding of the safety profiles of drugs being used. 相似文献
5.
6.
Sedigheh Farahani Leila Solgi Sahar Bayat Atieh Abedin Do Shohreh ZareKarizi Behnam Safarpour Lima Reza Mirfakhraie 《CNS Neuroscience & Therapeutics》2020,26(12):1315
AimsRAR‐related orphan receptor (RORA) involves in regulation of several biological processes including inflammation and circadian rhythm that probably are involved in migraine pathophysiology. In the current study, the association between RORA rs11639084 and rs4774388 variants and susceptibility to migraine were investigated in a sample of Iranian migraine patients for the first time.MethodsIn a case‐control study including 400 participants, 200 migraineurs and 200 healthy controls, genotyping of RORA rs4774388 and rs11639084 polymorphisms was performed using tetra‐primer amplification refractory mutation system–polymerase chain reaction (TP‐ARMS‐PCR).ResultsThe distribution of rs4774388 C/T and T/T genotypes differed significantly between the studied groups. Moreover, an association was observed between rs4774388 and migraine under the recessive mode of inheritance (P = 0.002; OR = 1.89.; CI = 1.25‐2.87). The distribution of rs11639084 alleles and genotypes was not significantly different between migraineurs and healthy controls.ConclusionCurrent results suggest RORA, as a molecular link, may explain inflammation and circadian rhythm dysfunction in migraine. Further studies in different ethnicities are required to confirm the function of RORA in migraine development. 相似文献
7.
8.
Iris Cervenka Marie Al Rahmoun Yahya Mahamat-Saleh Agnès Fournier Marie-Christine Boutron-Ruault Gianluca Severi Saverio Caini Domenico Palli Reza Ghiasvand Marit B. Veierod Edoardo Botteri Anne Tjønneland Anja Olsen Renée T. Fortner Rudolf Kaaks Matthias B. Schulze Salvatore Panico Antonia Trichopoulou Clio Dessinioti Katerina Niforou Sabina Sieri Rosario Tumino Carlotta Sacerdote Bas Bueno-de-Mesquita Torkjel M. Sandanger Sandra Colorado-Yohar Maria J. Sánchez Leire Gil Majuelo Leila Lujan-Barroso Eva Ardanaz Susana Merino Karolin Isaksson Salma Butt Ingrid Ljuslinder Malin Jansson Ruth C. Travis Kay-Tee Khaw Elisabete Weiderpass Laure Dossus Sabina Rinaldi Marina Kvaskoff 《International journal of cancer. Journal international du cancer》2020,146(12):3267-3280
Evidence suggests an influence of sex hormones on cutaneous melanoma risk, but epidemiologic findings are conflicting. We examined the associations between use of oral contraceptives (OCs) and menopausal hormone therapy (MHT) and melanoma risk in women participating in the European Prospective Investigation into Cancer and Nutrition (EPIC). EPIC is a prospective cohort study initiated in 1992 in 10 European countries. Information on exogenous hormone use at baseline was derived from country-specific self-administered questionnaires. We used Cox proportional hazards regression models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Over 1992–2015, 1,696 melanoma cases were identified among 334,483 women, whereof 770 cases among 134,758 postmenopausal women. There was a positive, borderline-significant association between OC use and melanoma risk (HR = 1.12, 95% CI = 1.00–1.26), with no detected heterogeneity across countries (phomogeneity = 0.42). This risk increased linearly with duration of use (ptrend = 0.01). Among postmenopausal women, ever use of MHT was associated with a nonsignificant increase in melanoma risk overall (HR = 1.14, 95% CI = 0.97–1.43), which was heterogeneous across countries (phomogeneity = 0.05). Our findings do not support a strong and direct association between exogenous hormone use and melanoma risk. In order to better understand these relations, further research should be performed using prospectively collected data including detailed information on types of hormone, and on sun exposure, which may act as an important confounder or effect modifier on these relations. 相似文献
9.
10.